Welcome to our dedicated page for Axogen SEC filings (Ticker: AXGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Axogen, Inc. (NASDAQ: AXGN) filings with the U.S. Securities and Exchange Commission, along with AI-assisted summaries to help interpret key disclosures. Axogen is a Minnesota-incorporated medical technology company focused on peripheral nerve repair and regeneration, and its filings offer detailed insight into financial performance, regulatory milestones, and corporate governance.
Through Axogen’s annual reports on Form 10-K and quarterly reports on Form 10-Q, readers can review audited and interim financial statements, risk factors, management’s discussion and analysis, and information on its portfolio of peripheral nerve repair products, including Avance (acellular nerve allograft-arwx), Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. These reports also discuss regulatory processes, reimbursement trends, and non-GAAP measures such as EBITDA and Adjusted EBITDA.
Current reports on Form 8-K capture material events, such as Axogen’s announcements regarding FDA review timelines and approval of the Biologics License Application for Avance, quarterly financial results, changes to executive compensation arrangements, and outcomes of annual shareholder meetings. Regulation FD disclosures within 8-K filings often furnish press releases and investor presentations related to earnings and regulatory updates.
Investors can also use this page to track proxy materials and shareholder vote results on matters like director elections, long-term incentive plans, advisory votes on executive compensation, and auditor ratification. Where available, Form 4 and other insider transaction filings can be consulted to monitor trading activity by directors and officers.
The platform’s AI-powered tools summarize lengthy filings, highlight important sections, and surface items such as Avance BLA developments, risk factor changes, and capital structure information, helping readers navigate Axogen’s SEC reporting more efficiently.
William P. Burke, a director of Axogen, Inc. (AXGN), reported multiple sales of common stock on
The Form 4 states the transactions were made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. After the reported transactions the schedule shows 2,293 shares held directly and 0 shares held indirectly by the trust in the most recent line, reflecting the post-transaction beneficial ownership reported on the form.
Axogen, Inc. (AXGN) submitted a Form 144 notice reporting a proposed sale of 736 common shares through Fidelity Brokerage Services LLC with an aggregate market value of $13,248.80 and an approximate sale date of 10/06/2025 on NASDAQ. The filer reports the shares were acquired in an open market purchase on 08/24/2023 and fully paid in cash.
The filing also discloses multiple recent sales by related parties within the prior days: four transactions on 10/02/2025 and 10/03/2025 totaling 36,264 shares with combined gross proceeds shown. The filing includes standard attestations about material nonpublic information and Rule 10b5-1 trading-plan references but provides no additional commentary or financial results.
Axogen, Inc. insider filing shows a proposed sale of 14,937 common shares, with an aggregate market value of $267,073.56, through Morgan Stanley Smith Barney LLC on 10/03/2025. The shares were acquired as Restricted Stock Units on 09/01/2024. The filer declares no undisclosed material information and notes reliance on Rule 144 and any applicable 10b5-1 trading plan mechanics. The notice also reports recent sales on 10/02/2025 totaling 10,020 shares for gross proceeds of $180,424.04 executed under a 10b5-1 program and an irrevocable trust.
Axogen, Inc. (AXGN) filed a Form 144 notice reporting a proposed open-market sale of 11,307 common shares with an aggregate market value of $206,316.82. The filing lists the broker as Fidelity Brokerage Services LLC and indicates the shares are to be sold on NASDAQ with an approximate sale date of 10/03/2025. The securities were acquired in two open-market purchases on 08/23/2023 (7,600 shares) and 08/24/2023 (3,707 shares), paid in cash. The filing also discloses a prior sale on 10/02/2025 of 2,400 shares by the Elizabeth J Burke 2024 Irrevocable Trust for gross proceeds of $43,224.00. The filer affirms they are not aware of undisclosed material adverse information.
Axogen, Inc. (AXGN) filed a Form 144 reporting a proposed sale of 2,400 common shares through Fidelity Brokerage Services LLC on 10/02/2025 on the NASDAQ. The filing lists the aggregate market value of the shares as $43,224.00 and reports 46,012,574 shares outstanding. The shares were originally acquired in an open market purchase on 08/23/2023 and paid in cash on that date. The filer reports no securities sold in the past three months and includes the standard representation that the selling person does not possess undisclosed material information about the issuer.
Axogen, Inc. insider filed a Form 144 notifying a proposed sale of 7,620 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $136,169.40. The filing lists the number of shares outstanding as 46,012,574 and an approximate sale date of 10/02/2025 on NASDAQ. The securities were acquired as Restricted Stock Units on 09/01/2024 from the issuer and the filing reports "Nothing to Report" for sales in the prior three months. The Form 144 includes the standard signature representation that the seller is not aware of undisclosed material adverse information.
Erick DeVinney, listed as Chief Innovation Officer and a director of Axogen, Inc. (AXGN), reported equity activity related to performance stock units. On 09/13/2025 2,500 shares of common stock were issued upon attainment of specified performance criteria, bringing his beneficial ownership to 221,786 shares. To satisfy tax withholding triggered by the vesting, the issuer's plan required a "sell-to-cover" transaction: on 09/16/2025 Mr. DeVinney sold 1,137 shares at $16.29 per share, reducing his beneficial ownership to 220,649 shares. The Form 4 indicates the sale was required by the company election under its equity incentive plans and was not a discretionary trade by the reporting person.
Axogen, Inc. reported that the U.S. Food and Drug Administration has classified its recent facility and manufacturing information submission as a Major Amendment to the Biologics License Application for Avance® Nerve Graft. As a result, the FDA extended the Prescription Drug User Fee Act goal date to December 5, 2025, a three-month delay consistent with FDA guidelines for major amendments. The FDA also now expects to provide feedback on product labeling in November 2025, giving a clearer timeframe for the next regulatory milestone.
FAQ
What is the current stock price of Axogen (AXGN)?
What is the market cap of Axogen (AXGN)?
